Home › Endometrial Cancer › New York › New York City
Endometrial Cancer clinical trials in New York City, NY
52 studies for Endometrial Cancer are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
- Mount Sinai Chelsea, New York
- Mount Sinai West, New York
- Mount Sinai Hospital, New York
- and 3 more
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of PHST001 in Advanced Solid Tumors
RecruitingPhase 1
- Mount Sinai, New York
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
- Memorial Sloan Kettering Hospital, New York
Study of AVZO-021 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, New York
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RecruitingPhase 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
Recruiting
- Memorial Sloan Kettering Cancer Center, New York
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RecruitingPhase 1
- Research Site, New York
- Research Site, New York
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RecruitingPhase 2
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RecruitingPhase 1
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (MSKCC), New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RecruitingPhase 3
- NYU Langone Health, New York
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RecruitingPhase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6004), New York
- Memorial Sloan Kettering Cancer Center ( Site 6053), New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
RecruitingPhase 3
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street, New York
- Perlmutter CC NYU Langone LI, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RecruitingPhase 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, New York
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
RecruitingPhase 1
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RecruitingPhase 1
- Icahn School of Medicine at Mount Sinai, New York
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RecruitingPhase 2
- Laura & Isaac Perlmutter Cancer Center, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Mount Sinai Health System, New York
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
RecruitingObservational study
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
RecruitingObservational studyHealthy volunteers welcome
- NYP/Weill Cornell Medicine, New York
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RecruitingPhase 1/2
- New York University Langone Health, New York
- ICHAN School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
RecruitingEarly phase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4175408 in Participants With Advanced Cancer
RecruitingPhase 1
- Columbia University, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of a Weight Loss Intervention in People With Endometrial Cancer
RecruitingEarly phase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RecruitingPhase 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer
Recruiting
- Memorial Sloan Kettering Cancer Center, New York
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, New York
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RecruitingPhase 1/2
- NYU Langone Health, New York
Comprehensive Outcomes for After Cancer Health
RecruitingHealthy volunteers welcome
- Memorial Sloan Kettering Cancer Center, New York
Endometrial Cancer trials in other cities
- Houston, TX68 studies
- Boston, MA50 studies
- Arlington, VA39 studies
- Nashville, TN38 studies
- Los Angeles, CA34 studies
- St. Louis, MO29 studies
- Philadelphia, PA28 studies
- San Antonio, TX27 studies
- Columbus, OH25 studies
- Chicago, IL25 studies
- Oklahoma City, OK25 studies
- Queens, NY25 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Acute Myeloid Leukemia51 studies
- Heart Failure51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.